Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NYSE /
  3. ANRO.NYSE

Alto Neuroscience, Inc. (ANRO NYSE) stock market data APIs

$14.74 0.38(2.6%) as of July 26, 2024
Price chart is built with Anychart

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Alto Neuroscience, Inc. Financial Data Overview

14.36
14.74
-
14.74
14.23
9.4-24
0
0
0
-0.4991
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ANRO',
Type: 'Common Stock',
Name: 'Alto Neuroscience, Inc.',
Exchange: 'NYSE',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00WYFS6R5',
ISIN: NULL,
CUSIP: NULL,
CIK: '1999480',
EmployerIdNumber: NULL,
FiscalYearEnd: 'September',
IPODate: '2024-02-02',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Alto Neuroscience, Inc. Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA 0
  • Earnings Per Share
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Alto Neuroscience, Inc. Earnings via APIs

  • Latest Release 2024-05-15
  • EPS/Forecast NaN

Get Alto Neuroscience, Inc. End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Alto Neuroscience, Inc. latest news via APIs

Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On

One of the best ways to be successful in the stock market is by identifying under-the-radar stocks before they blow up. All of today’s biggest and most valuable companies were once entirely unknown....

Insiders are Piling into These 10 Healthcare Stocks in 2024

In this article, we will take a detailed look at Insiders are Piling into These 10 Healthcare Stocks in 2024. For a quick overview of such stocks, read our articleInsiders are Piling into These 5 Hea...
Do you have any questions?
support@eodhistoricaldata.com